
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical Inc. is anticipated to achieve robust top-line growth, with expectations for the global orthopedics business to show sustainable growth of at least mid-to-upper single digits, driven by distribution expansion and deeper account penetration. The company’s adjusted EBITDA margin is projected to increase significantly from 8.4% in 2024 to 13.5% by 2027, indicating a positive trajectory in profitability. Additionally, the shift towards positive and growing free cash generation starting in the second half of 2025 further enhances the company's financial outlook, suggesting strong operational performance in the coming years.
Bears say
Orthofix Medical Inc. faces a challenging financial outlook characterized by an anticipated net interest expense ranging from $19 million to $20 million for fiscal year 2025, potentially limiting profitability and impacting free cash flow generation in the subsequent years. The company's adjusted EBITDA margins in its orthopedics segment are notably low at 3.7% for fiscal year 2024, exacerbated by SG&A expenses that significantly exceed projections, suggesting ongoing operational inefficiencies. Additionally, despite positive growth trends within the spine and orthopedic markets, the company's innovation and product development have lagged, leading to a valuation that remains just above 52-week lows and a disappointing growth rate following earlier projections.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares